949 / 1266
Phase 1 study of dabrafenib in pediatric patients with
relapsed or refractory BRAFV600-mutant high-grade
gliomas, low-grade gliomas, histiocytosis, and other solid
tumors
Mark W Kieran
1
, Darren Hargrave
2
, Ken Cohen
3
, Isabelle Aerts
4
,
Ira J Dunkel
5
, Trent R Hummel
6
, Irene Jimenez
4
, Andrew Pearson
7
, Christine Pratilas
3
, James
Whitlock
8
, Eric Bouffet
8
, Violet Shen
9
,
Alberto Broniscer
10
, Anne-Isabelle Bertozzi
11
, Joan Sandberg
12
*,
Allison Florance
12
*, Benjamin Suttle
12
§
, Patricia Haney
12†
, Mark Russo
12
*, Birgit Geoerger
13
1
Dana-Farber Cancer Institute and Boston Children
’
s Hospital, Boston, MA, USA;
2
Great Ormond Street Hospital for Children, London, UK;
3
Johns Hopkins University
School of Medicine, Baltimore, MD, USA;
4
Curie Institute, Paris France;
5
Memorial Sloan Kettering Cancer, New York, NY, USA;
6
Cincinnati Children's Hospital Medical
Center, Cincinnati, OH, USA;
7
The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK;
8
Hospital for Sick Children, Toronto, Ontario,
Canada;
9
Children's Hospital of Orange County, Orange, CA, USA;
10
St. Jude Children's Research Hospital, Memphis, TN, USA;
11
CHU de Toulouse - Hôpital des Enfants,
Toulouse, France;
12
GlaxoSmithKline, RTP, NC, USA;
13
Gustave Roussy, Villejuif, France
*
Current affiliation
: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;
§
Current affiliation
: Salix Pharmaceuticals, Raleigh, NC, USA;
†
Current affiliation
: Pfizer Inc, New York, NY, USA